197 related articles for article (PubMed ID: 12777976)
1. The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.
Robinson WA; Miller TL; Harrold EA; Bemis LT; Brady BM; Nelson RP
Melanoma Res; 2003 Jun; 13(3):231-8. PubMed ID: 12777976
[TBL] [Abstract][Full Text] [Related]
2. Flavopiridol Induces Apoptosis via Mitochondrial Pathway in B16F10 Murine Melanoma Cells and a Subcutaneous Melanoma Tumor Model.
Gokce O; Dogan Turacli I; Ilke Onen H; Erdem O; Erguven Kayaa E; Ekmekci A
Acta Dermatovenerol Croat; 2016 Apr; 24(1):2-12. PubMed ID: 27149123
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition and induction of apoptosis by flavopiridol in rat lung adenocarcinoma, osteosarcoma and malignant fibrous histiocytoma cell lines.
Honoki K; Yoshitani K; Tsujiuchi T; Mori T; Tsutsumi M; Morishita T; Takakura Y; Mii Y
Oncol Rep; 2004 May; 11(5):1025-30. PubMed ID: 15069542
[TBL] [Abstract][Full Text] [Related]
4. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS
J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881
[TBL] [Abstract][Full Text] [Related]
5. Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity.
Jiang J; Matranga CB; Cai D; Latham VM; Zhang X; Lowell AM; Martelli F; Shapiro GI
Cancer Res; 2003 Nov; 63(21):7410-22. PubMed ID: 14612540
[TBL] [Abstract][Full Text] [Related]
6. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines.
Shapiro GI; Koestner DA; Matranga CB; Rollins BJ
Clin Cancer Res; 1999 Oct; 5(10):2925-38. PubMed ID: 10537362
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Dai Y; Rahmani M; Grant S
Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
[TBL] [Abstract][Full Text] [Related]
8. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells.
Schrump DS; Matthews W; Chen GA; Mixon A; Altorki NK
Clin Cancer Res; 1998 Nov; 4(11):2885-90. PubMed ID: 9829756
[TBL] [Abstract][Full Text] [Related]
9. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
Raju U; Nakata E; Mason KA; Ang KK; Milas L
Cancer Res; 2003 Jun; 63(12):3263-7. PubMed ID: 12810657
[TBL] [Abstract][Full Text] [Related]
10. In vitro study examining the effect of sub-lethal QS 755 nm lasers on the expression of p16INK4a on melanoma cell lines.
Chan HH; Xiang L; Leung JC; Tsang KW; Lai KN
Lasers Surg Med; 2003; 32(2):88-93. PubMed ID: 12561040
[TBL] [Abstract][Full Text] [Related]
11. Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo.
Wirger A; Perabo FG; Burgemeister S; Haase L; Schmidt DH; Doehn C; Mueller SC; Jocham D
Anticancer Res; 2005; 25(6B):4341-7. PubMed ID: 16309238
[TBL] [Abstract][Full Text] [Related]
12. Flavopiridol as a radio-sensitizer for esophageal cancer cell lines.
Sato S; Kajiyama Y; Sugano M; Iwanuma Y; Tsurumaru M
Dis Esophagus; 2004; 17(4):338-44. PubMed ID: 15569374
[TBL] [Abstract][Full Text] [Related]
13. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma.
Koenig A; Bianco SR; Fosmire S; Wojcieszyn J; Modiano JF
Vet Pathol; 2002 Jul; 39(4):458-72. PubMed ID: 12126149
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer.
Chien M; Astumian M; Liebowitz D; Rinker-Schaeffer C; Stadler WM
Cancer Chemother Pharmacol; 1999; 44(1):81-7. PubMed ID: 10367753
[TBL] [Abstract][Full Text] [Related]
15. Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines.
Mayer F; Mueller S; Malenke E; Kuczyk M; Hartmann JT; Bokemeyer C
Invest New Drugs; 2005 Jun; 23(3):205-11. PubMed ID: 15868376
[TBL] [Abstract][Full Text] [Related]
16. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.
Shapiro GI
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4270s-4275s. PubMed ID: 15217973
[TBL] [Abstract][Full Text] [Related]
17. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.
Raju U; Ariga H; Koto M; Lu X; Pickett J; Valdecanas D; Mason KA; Milas L
Radiother Oncol; 2006 Aug; 80(2):185-91. PubMed ID: 16905211
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
Nguyen DM; Schrump WD; Tsai WS; Chen A; Stewart JH; Steiner F; Schrump DS
J Thorac Cardiovasc Surg; 2003 May; 125(5):1132-42. PubMed ID: 12771887
[TBL] [Abstract][Full Text] [Related]
19. Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase.
Matranga CB; Shapiro GI
Cancer Res; 2002 Mar; 62(6):1707-17. PubMed ID: 11912144
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol.
Smith V; Raynaud F; Workman P; Kelland LR
Mol Pharmacol; 2001 Nov; 60(5):885-93. PubMed ID: 11641415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
